News

PromarkerD significantly outperforms current standard of care tests in predicting future kidney function decline – Market Watch

The research, presented at Kidney Week 2021, the annual meeting of the American Society of Nephrology (ASN), compared the PromarkerD test to current standard of care tests, the estimated glomerular filtration rate (eGFR) and urinary albumin:creatinine ratio (ACR). The study updates and extends previous analysis and constitutes a core body of evidence underpinning the performance of PromarkerD for submissions to global regulators.

Article: PromarkerD significantly outperforms current standard of care tests in predicting future kidney function decline

Subscribe
  • This field is for validation purposes and should be left unchanged.